Literature DB >> 6419136

Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhotics.

R M Pérez-Ayuso, V Arroyo, J Camps, W Jiménez, M Rodamilans, A Rimola, J Gaya, F Rivera, J Rodés.   

Abstract

8 cirrhotics with hyponatremia were given demeclocycline (DMC) 900 mg/day to investigate its effect on renal function, plasma renin activity, aldosterone and urinary excretion of prostaglandin E2 and kallikrein. In 7 patients DMC induced an increase of free water clearance (from -0.36 +/- 0.06 to 0.13 +/- 0.06 ml/min) and serum sodium concentration (from 125.4 +/- 0.09 to 131.1 +/- 1.0 mEq/l, mmol/l). In 5 of these patients DMC also induced a marked reduction of glomerular filtration rate (from 72.2 +/- 6.2 to 31,2 +/- 4.7 ml/min) and renal plasma flow (from 468 +/- 98 to 195 +/- 55 ml/min) which could not be explained on the basis of hypovolemia. In each case this renal impairment was not associated with changes in urinary concentration of beta 2-microglobulin, urinary casts excretion, fresh urine sediment or urine protein content and disappeared after discontinuation of the drug. DMC induced a marked increase in the urinary excretion of prostaglandin E2 (from 0.82 +/- 0.27 to 6.16 +/- 1.91 ng/min) in 6 out of the 7 patients who responded to DMC and a marked reduction in urinary kallikrein (from 16.1 +/- 4.4 to 4.2 +/- 1.6 pkat/min) in the 5 patients who developed renal insufficiency. The serum DMC concentration was greater than 5 micrograms/ml in all patients who responded to DMC, greater than 8 micrograms/ml in all cases who developed renal insufficiency and of 3 micrograms/ml in the case not responding to DMC. (ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6419136     DOI: 10.1159/000183112

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

1.  Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention.

Authors:  Josefa Ros; Guillermo Fernández-Varo; Javier Muñoz-Luque; Vicente Arroyo; Juan Rodés; Joseph W Gunnet; Keith T Demarest; Wladimiro Jiménez
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites.

Authors:  P A McCormick; P Mistry; G Kaye; A K Burroughs; N McIntyre
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

4.  Use of urea for treatment of water retention in hyponatraemic cirrhosis with ascites resistant to diuretics.

Authors:  G Decaux; P Mols; P Cauchi; F Delwiche
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15

Review 5.  Traditional management of liver disorders.

Authors:  M Messner; P Brissot
Journal:  Drugs       Date:  1990       Impact factor: 9.546

6.  The role of nitric oxide in the expression of renal aquaporin 2 in a cirrhotic rat model: does an AVP-independent mechanism exist for the regulation of AQP2 expression?

Authors:  Dae Won Jun; Jin Hee Park; Yoo Sin Park; Ju-Seop Kang; Eun Kyung Kim; Kyung Tae Kim; Byoung Kwan Son; Seong Hwan Kim; Yun Ju Jo; Young Sook Park
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.